RxDoctor Payments Data

Billie Bixby, MD

Pulmonary Disease · Tucson, AZNPI 1770801938

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (43.1%), travel and lodging and education — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Boston Scientific at 47.0% of the total. Reporting peaked in 2019 at $18,104 and has fallen 94.4% since, to $1,011 in 2025. Among pulmonary disease clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$34,843in general payments, 2019–2025

Across 105 payments — averaging $331.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$16K
  • Intuitive Surgical$11K
  • Steris Corporation$2K
  • Pulmonx Corporation$2K
  • Johnson & Johnson$1K
  • Noah Medical Corporation$903
  • plus $2K from 11 others
$37,239in research payments, 2019–2025

Across 5 payments — averaging $7447.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$37K

What the payments were for

  • Grants$15,00043%
  • Travel & lodging$8,58425%
  • Food & beverage$5,24515%
  • Education$6,00017%
  • Gifts$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,843 in reported general payments places this provider in the 90th percentile of 250 pulmonary disease providers in Arizona.

See all pulmonary disease providers in Arizona

Medicare billing

Part B allowed, 2024
$71,824
Medicare patients
204
Services billed
680

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$56,541
Spiriva RespimatTiotropium Bromide20$19,032
SymbicortBudesonide/Formoterol Fumarate18$4,141
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$2,397
Varenicline Tartrate12$2,383
Albuterol Sulfate HfaAlbuterol Sulfate100$2,007
Wixela InhubFluticasone Propion/Salmeterol11$1,032
Prednisone52$110
Azithromycin36$98

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →